DEA Slapped in Face: American Epilepsy Society Accepts Marijuana Extract Obliterates Seizures in Epileptic Children


As the United States Drug Enforcement Agency (DEA) continues to display its arrogance, refusing to remove marijuana from schedule 1 of the Control Substance Act (CSA), thanks to certified professional bodies in the country, more and more details on medical efficacy of the plant is being revealed.

On August 11, 2016 the DEA turned down two petitions. One was from the governors of Rhode Island and Washington, and the other from a resident of New Mexico, requesting that marijuana be removed from Schedule I of the CSA. The removal from schedule I would have ensured that official scientific research is carried on the plant, across the United States.

s 1

But the DEA still held that marijuana has high abuse potential; no medical use; severe safety concerns; and that there is no available scientific research to prove otherwise.

This arrogant DEA response has angered Washington state officials, who are now saying that the state will defy the federal ban to issue licenses to laboratories in the state to grow the marijuana for scientific study.

Also, a study conducted recently by two researchers from the University of Georgia shed more light on the medicinal and economic benefits of marijuana. The study, published in the journal Health Affairs, revealed that legalizing marijuana for medicinal purposes has helped the United States save $165.2 million in medical care costs in 2013, alone.

To add to the growing body of evidence of medical prowess of marijuana, a medical charity in Illinois – the American Epilepsy Society (AES) – has now announced, that a study it supervised has proven that marijuana is an effective cure for seizures, especially in children. The AES has accepted the study in its online journal.

s 2

The heartwarming announcement was made at the annual meeting of the AES. It is said the study was the largest ever study showing marijuana is capable of curing seizures.


According to statistics, epilepsy affects one in 26 Americans during their lifetime. One-third is said to have a form of the condition that resists treatment or effective management. However, children and young adults are the most vulnerable to this devastating condition.

According to the study, Cannabidiol (CBD), a non-psychoactive extract of cannabis, can provide the best option for the treatment of epilepsy, especially in children.

s 4

During the study, 261 patients were given CBD treatment. The results showed that 45% experienced a significant reduction in seizure frequency, with 9% seizure-free just in three months of CBD being administered.  The researcher said, even after the study, some children continued to benefit from the plant.

Lead author of the study, Dr Orrin Devinsky said: “In the subsequent periods, which are very encouraging, 9 percent of all patients and 13 percent of those with Dravet Syndrome epilepsy were seizure-free. Many have never been seizure-free before.”

In the past, The Free Thought Project has covered many stories of CBD providing miraculous benefits to children suffering from treatment-resistant epileptic seizures.

With scientific evidence piling up, it is no longer deniable that cannabis provides a host of medical treatments, including treating seizures. Many commentators in the United States now believe the DEA and the federal government should lift the ban on marijuana, in order to allow more scientific research to be conducted on the plant.

“As a practitioner, I have had families move to Colorado, and many tried multiple different products. As a doctor, I often don’t feel like I know which of many factors is contributing to a patient doing better or worse. We absolutely need rigorous, scientific data on this,” Dr Devinsky added.

You want to support Anonymous Independent & Investigative News? Please, follow us on Twitter: Follow @AnonymousNewsHQ

This article (DEA Slapped in Face: American Epilepsy Society Accepts Marijuana Extract Obliterates Seizures in Epileptic Children) is a free and open source. You have permission to republish this article under a Creative Commons license with attribution to the author and


  1. As a Pharmacist who has researched medical cannabis, I’m still furious that the DEA would use the FDA as a scapegoat for rescheduling. If I could suggest a project, it would be to hack the FDA and find the proof that there is collusion between the FDA and DEA. There are many published studies on medical cannabis, but the FDA basically refuses to acknowledge them due to their origin (europe, UK, etc) while they have no problem accepting data for other classes of medications. The major statins used today are based on research from those areas, but the FDA has no “evidence” for medical use when it comes to cannabis. I have already counseled patients who are using cannabis for chronic pain and they have been able to curb opiate addiction and the side effects that come with their use (GI issues, pain intolerance). The university of michigan published a study in 2016 showing that long term opiate users (addicts) are able to lower their dosages of prescription drugs (norco, fentanyl, percocet, etc) all from using cannabis. There are literally over 20+ uses for cannabis which would lower prescription costs and healthcare costs overall if we could just research as a schedule II drug. On the flip side, the FDA is okay with approving ketamine for depression….because it is backed by Janssen Pharmaceuticals and there’s $$$ to be made. Having a top 5 party drug go on prescription to depressed people…Brilliant. If there’s anyone who could do it, a lot of people could be helped and a lot of health care expenses could be reduced.

  2. The data comes from trials conducted by GW Pharma using their drug epidiolex which is pure CBD. The FDA has given this UK based company both orphan drug designation and fast track approval for four different types of epilepsy (dravet syndrome, lennox-gastaut syndrome, tuberous sclerosis and infantile spasms). The company has already proven it works in dravet and LGS They are now in talks with the FDA and hope the drug will be approved in these some time next year. Trials for the other types are ongoing worldwide as we speak. Should these show the drug works better than the control group (SOC + placebo) then it should be approved as well. In addition to all of this then trials are going using pure CBDV (GWP42006) in focal seizures.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.